Research Article
Cardiovascular Outcomes in Patients on Hemodialysis following Drug-Eluting versus Bare-Metal Coronary Stents
Table 1
Demographic, clinical, and procedural characteristics of patients before the propensity match.
| | Characteristic | BMS | DES | value, DES versus BMS | | () | () |
| | Women | 43 (32.09) | 151 (32.90) | 0.861 | | Age (years) | 67.54 ± 11.90 | 66.26 ± 12.4 | 0.29 | | Race | | | 0.128 | | White | 110 (82.09) | 360 (78.77) | | | African American | 8 (5.97) | 47 (10.28) | | | Hispanic | 7 (5.22) | 25 (5.47) | | | Others | NA | 18 (3.94) | | | Insurance | | | 0.244 | | Government | 93 (69.40) | 330 (71.90) | | | Commercial | NA | 60 (13.07) | | | HMO | 24 (17.91) | 69 (15.03) | | | No insurance | NA | 0 (0.00) | | | Past medical history | | | | | Prior MI | 53 (39.55) | 218 (47.49) | 0.105 | | CHF | 58 (43.28) | 182 (39.65) | 0.452 | | Diabetes | 77 (57.46) | 306 (66.67) | 0.05 | | Cerebrovascular disease | 42 (31.34) | 94 (20.48) | 0.015 | | Peripheral vascular disease | 54 (40.30) | 192 (41.83) | 0.752 | | Chronic lung disease | 24 (17.91) | 100 (21.79) | 0.333 | | Hypertension | 126 (94.03) | 428 (93.25) | 0.748 | | Dyslipidemia | 111 (82.84) | 362 (78.87) | 0.315 | | Family history of CAD | 32 (23.88) | 132 (28.76) | 0.268 | | Prior PCI | 23 (17.16) | 127 (27.67) | 0.007 | | Prior CABG | 40 (29.85) | 115 (25.05) | 0.267 | | Current smoker | 18 (13.43) | 56 (12.20) | 0.705 | | Former smoker | 73 (54.48) | 242 (52.72) | 0.721 | | Never smoked | 43 (32.09) | 161 (35.08) | 0.523 | | Presentation | | | 0.111 | | ST-elevation MI | 17 (12.69) | 30 (6.54) | | | Non-ST-elevation MI | 43 (32.09) | 157 (34.20) | | | Unstable angina | 30 (22.39) | 112 (24.40) | | | Stable angina | 11 (8.21) | 54 (11.76) | | | Noninvasive test outcome | | | 0.44 | | No test | 40 (29.85) | 170 (37.04) | | | Positive | 74 (55.22) | 228 (49.67) | | | Negative | 11 (8.21) | 38 (8.28) | | | Equivocal | 9 (6.72) | 23 (5.01) | | | Congestive heart failure | 58 (43.28) | 143 (31.15) | 0.009 | | NYHA classification | | | 0.724 | | 3 | 23 (17.16) | 50 (10.89) | | | 4 | 25 (18.66) | 57 (12.42) | | | PCI status | | | 0.298 | | Elective | 44 (32.84) | 171 (37.25) | | | Urgent | 69 (51.49) | 241 (52.51) | | | Emergency | 20 (14.93) | 46 (10.02) | | | Left ventricular ejection fraction <30% | 37 (27.61) | 133 (28.98) | 0.759 | | Number of vessels with lesions >50% | | | 0.851 | | 1 | 114 (85.07) | 385 (83.88) | | | 2 | 19 (14.18) | 68 (14.81) | | | ≥3 | NA | NA | | | Proximal LAD disease | 16 (11.94) | 87 (18.95) | 0.038 | | Left main disease | 7 (5.22) | 20 (4.36) | 0.673 | | High-risk lesion complexity | 57 (42.54) | 172 (37.47) | 0.29 | | Number of vessels intervened on | 1.16 ± 0.38 | 1.18 ± 0.42 | 0.589 | | Number of stents used, total | 1.48 ± 0.83 | 1.64 ± 0.99 | 0.045 | | Per lesion | 1.16 ± 0.58 | 1.16 ± 0.56 | 0.924 | | Per vessel | 0.37 ± 0.21 | 0.41 ± 0.25 | 0.045 | | Periprocedural medications | | | | | Thrombin inhibitors-bivalirudin | 20 (25.64) | 80 (30.42) | 0.417 | | Heparin† | 60 (44.78) | 205 (44.66) | 0.981 | | ASA | 126 (94.03) | 453 (98.69) | 0.03 | | Clopidogrel | 75 (55.97) | 275 (59.91) | 0.415 | | Glycoprotein IIb/IIIa inhibitor use | 15 (11.19) | 76 (16.56) | 0.099 |
|
|
Continuous variables are expressed as mean ± standard deviation and categorical variables as number (percentage); BMS, bare-metal stent; DES, drug-eluting stent; MI, myocardial infarction; CHF, congestive heart failure; CAD, coronary artery disease; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; NYHA, New York Heart Association; †unfractionated and low molecular weight heparin. |
